CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
Interferon Gamma-1bdrug
Likely dose
Interferon Gamma-1b 0.2 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01376362
NCT01376362Phase 2Completed
CompareCT.gov

The Treatment of Macular Edema Secondary to Uveitis Using Topical Interferon Gamma

National Eye Institute (NEI)·interventional·Posted Jun 20, 2011·Updated Oct 8, 2012

In Brief

A Phase 2 clinical trial evaluating Interferon Gamma-1b for Anterior Uveitis and Uveitis. Completed, enrolled 5 participants across 1 site.

Detailed Summary

The objective of this study is to investigate the safety and efficacy of ocular instillations of interferon gamma-1b as a potential treatment for cystoid macular edema (CME) secondary to uveitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnterior Uveitis, Uveitis
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 20, 2011
Enrollment StartJun 1, 2011
Primary CompletionFeb 1, 2012
Study CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 15.0 years ago

Interventions

Interferon Gamma-1bdrug

Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.